Gene Grant Finley - Concepedia

Author

Gene Grant Finley

Also Known As

Fabrice Barlesi, G Finley, G G Finley, G. FINLEY, G. Finley, Gene Finley, Gene G Finley, Gene G. Finley, Gene Grant Finley

116

Publications

8.3K

Citations

H-Index

Concepts

All Affiliations

Allegheny Health Network Florida Hospital Cancer Institute Rocky Mountain Cancer Centers Hospital Universitario Insular de Gran Canaria Aix-Marseille Université

About

Gene Grant Finley is an author at Allegheny Health Network specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.6K
2	Health Sciences	5	5	113
3	Cell Biology	2	2	562
4	Clinical Immunology	1	1	21
5	Epidemiology	1	1	21

Gene Grant Finley

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, New England Journal of Medicine	2018	3.7K
<i>WISP</i> genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors Diane Pennica, Todd A. Swanson, James W. Welsh, Proceedings of the National Academy of Sciences PathologyWisp InductionCancer BiologyTumor BiologySignaling Pathway	1998	510
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Mark A. Socinski, Makoto Nishio, Robert M. Jotte, Journal of Thoracic Oncology	2021	483
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Journal of Thoracic Oncology Neuro-oncologyAtezolizumab Plus BevacizumabMedicinePathologyCancer Treatment	2021	283
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study John H. Strickler, Andrea Cercek, Salvatore Siena, The Lancet Oncology OncologyMedicinePathologyColorectal CancerMetastatic Colorectal Cancer	2023	217
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, JAMA Oncology	2023	172
Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer Shaakir Hasan, Paul Renz, Rodney E. Wegner, Annals of Surgery	2018	149
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Journal of Clinical Oncology OncologyPd-l1 ExpressionMedicine± BevacizumabImmunology	2018	87
Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. Gene Grant Finley, Raymond A. Koski, M F Melhem, PubMed Gastric AntrumGastrointestinal OncologyGastrin GeneGeneticsImmunology	1993	62
Alternative Splicing of CD44 pre-mRNA in Human Colorectal Tumors L A Finn, G J Dougherty, Gene Grant Finley, Biochemical and Biophysical Research Communications Tumor BiologyMedicineRna SplicingColorectal CancerPathology	1994	53

Page 1